Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Aventis File For Exubera In Europe; No Timeline Yet On U.S. NDA

Executive Summary

Pfizer and Aventis have filed for European regulatory approval of the inhaled insulin Exubera

You may also be interested in...



Pfizer Exubera Post-Market Training Needs Greater Emphasis – Cmte.

Pfizer/Sanofi-Aventis' post-marketing training program for administering the inhaled insulin powder Exubera with a novel mechanical inhaler needs greater focus, FDA's Endocrinologic & Metabolic Drugs Advisory Committee said in a Sept. 8 review

Pfizer Exubera Post-Market Training Needs Greater Emphasis – Cmte.

Pfizer/Sanofi-Aventis' post-marketing training program for administering the inhaled insulin powder Exubera with a novel mechanical inhaler needs greater focus, FDA's Endocrinologic & Metabolic Drugs Advisory Committee said in a Sept. 8 review

Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?

Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid

Related Content

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel